Research ArticleArticle
The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7
Jana C. Precht, Werner Schroth, Kathrin Klein, Hiltrud Brauch, Evgeny Krynetskiy, Matthias Schwab and Thomas E. Mürdter
Drug Metabolism and Disposition November 2013, 41 (11) 1906-1913; DOI: https://doi.org/10.1124/dmd.113.053405
Jana C. Precht
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
Werner Schroth
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
Kathrin Klein
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
Hiltrud Brauch
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
Evgeny Krynetskiy
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
Matthias Schwab
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
Thomas E. Mürdter
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Letrozole Metabolite Carbinol as Probe Drug for UGT2B7
Jana C. Precht, Werner Schroth, Kathrin Klein, Hiltrud Brauch, Evgeny Krynetskiy, Matthias Schwab and Thomas E. Mürdter
Drug Metabolism and Disposition November 1, 2013, 41 (11) 1906-1913; DOI: https://doi.org/10.1124/dmd.113.053405
Research ArticleArticle
Letrozole Metabolite Carbinol as Probe Drug for UGT2B7
Jana C. Precht, Werner Schroth, Kathrin Klein, Hiltrud Brauch, Evgeny Krynetskiy, Matthias Schwab and Thomas E. Mürdter
Drug Metabolism and Disposition November 1, 2013, 41 (11) 1906-1913; DOI: https://doi.org/10.1124/dmd.113.053405
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement